CG Oncology Hits New 52-Week High of $76.50, Up 101.73%

CG Oncology, Inc. has reached a significant milestone by hitting a new 52-week high of USD 76.50 on June 30, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 101.73% rise over the past year, significantly outpacing the S&P 500's growth of 20.86% during the same period. As a small-cap company within the miscellaneous industry, CG Oncology has a market capitalization of USD 5,456 million. Despite its recent price surge, the company remains in a loss-making position, with a negative return on equity of -21.39%. The stock's price-to-book ratio stands at 7.25, indicating a premium valuation relative to its book value. The stock's previous 52-week low was recorded at USD 23.65, highlighting the substantial recovery and growth it has experienced. Investors and market observers will be keen to monitor how CG Oncology continues to navigate its financial landscape following this notable achievement.